Navigation Links
Cepheid Reports 2013 First Quarter Results
Date:4/18/2013

7.421.428%Non-Clinical & Other

0.91.5-40%Total International28.322.924%Total Sales$
91.9$
77.319%


  • During the quarter, Cepheid installed a total of 125 GeneXpert systems in its commercial Clinical business.  Additionally, the Company placed a total of 157 GeneXpert systems as part of its High Burden Developing Country (HBDC) program.  Including the HBDC systems, a cumulative total of 4,117 GeneXpert systems have been placed worldwide as of March 31, 2013.
  • GAAP gross margin on sales was 53% and non-GAAP gross margin on sales was 55%, which compares to 54% and 55%, respectively, in the first quarter of 2012. 
  • Cash and cash equivalents were $102.0 million as of March 31, 2013.
  • DSO was 45 days.
  • Business OutlookFor the fiscal year ending December 31, 2013, the Company continues to expect:

  • Total revenue to be in the range of $375 to $385 million;
  • Net income to range from a net loss of $(0.05) to net income of $0.01 per share; 
  • Non-GAAP net income in the range of $0.41 to $0.46 per share. 
  • Expected non-GAAP net income excludes approximately $29 million related to stock compensation expense and approximately $4 million related to the amortization of acquired intangibles.  The fully diluted share count for the year is expected to be approximately 72 million, except in the event of a GAAP loss where the share count would be approximately 67 million shares.

    The following table reconciles net income (loss) per share to the non-GAAP net income per share range:Guidance Range for YearEnding December 31, 2013Low HighNet Income (Loss) Per Share$
    (0.05)$
    .01Stock Compensation Expense0.400.39Amortization of Purchased Intangible Assets0.060.06Non-GAAP Measure of Net Income Per Share$
    .41$
    .46Accessing Cepheid's 2013 First Quarter Results Conference CallThe Company will host a management presentation at 2 p.m. Pacific Time on
    '/>"/>

    SOURCE Cepheid
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related biology technology :

    1. Testing Positive for Stability & Growth - Research Report on CombiMatrix Corporation, Cepheid, PerkinElmer, Inc., Life Technologies Corp. and Laboratory Corp. of America Holdings
    2. Cepheid Announces Board of Directors Changes
    3. Cepheid Reports 2012 Second Quarter Results
    4. Cepheid Receives FDA Clearance for GeneXpert Infinity-80 System for Initial Use with Xpert Flu Assay
    5. Cepheid Announces European Release of Xpert CT/NG and Xpert CT, Delivering Rapid Detection and Differentiation of Chlamydia and Gonorrhoeae
    6. Diagnostic Marketing Association Names Cepheid 2011 Marketer of the Year
    7. Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria
    8. Cepheid to Webcast Upcoming Financial Presentations
    9. Cepheid Reports Fourth Quarter and Full Year 2011 Results
    10. Cepheid Welcomes Senior Vice President of Human Resources
    11. Global Nano-Materials Market 2002-2016: Nano-Materials Industry, Production Volumes, Revenues and End User Market Demand - MarketResearchReports.Biz
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/27/2014)... 2014 The Europe Thermal Protective ... to provide crucial revenue forecasts. It estimates the ... at a CAGR of 7.5%, from 2013 to ... Europe Thermal Protective Clothing market report for a ... supported by various tables and figures. , ...
    (Date:11/27/2014)... Nov. 27, 2014 Research and ... "Global Palmitic Acid Industry Report 2014" report to ... The Global Palmitic Acid Industry Report 2014 ... state of the global palmitic acid industry. ... including definitions, classifications, applications and industry chain structure. The ...
    (Date:11/27/2014)... 2014 Spartan Bioscience today announced that ... Drug Safety (MFDS) regulatory approval for its Spartan ... in less than 60 minutes from a non-invasive cheek ... aid for doctors to determine therapeutic strategies for drugs ... some of the world’s most commonly prescribed drugs such ...
    (Date:11/27/2014)... November 27, 2014 First ...   Elsevier , a world-leading provider ... is pleased to announce the launch of a new ... The launch of Extreme Mechanics ... at the forefront of applied sciences such as micro ...
    Breaking Biology Technology:The Europe Thermal Protective Clothing market is estimated to grow up to $577.9 million by 2018 - Report by MicroMarket Monitor 2The Europe Thermal Protective Clothing market is estimated to grow up to $577.9 million by 2018 - Report by MicroMarket Monitor 3Global Palmitic Acid Industry Report 2014 2Spartan Bioscience Receives Korean Regulatory Approval for First Rapid DNA Test of Mutations Affecting Metabolism of Common Drugs 2Spartan Bioscience Receives Korean Regulatory Approval for First Rapid DNA Test of Mutations Affecting Metabolism of Common Drugs 3Elsevier Announces the Launch of a New Journal: Extreme Mechanics Letters 2Elsevier Announces the Launch of a New Journal: Extreme Mechanics Letters 3
    ... Inc., today,announced the appointment of Lynn Marcus-Wyner, Ph.D., ... for managing the company,s,intellectual property strategy, activities, and ... President, General Counsel and Secretary., Dr. Marcus-Wyner ... Intellectual Assets US, she managed the United States ...
    ... Sept. 23 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc.,(TSX: SDI) ... terms with Toray,Industries Inc. of Japan to obtain ... for Toraymyxin(TM), a therapeutic for the treatment of,sepsis ... terms of the,agreement, the Company will seek FDA ...
    ... BROOMFIELD, Colo., Sept. 23 ARCA biopharma, ... Drug Administration (FDA) has,accepted a New Drug ... bucindolol, an investigational and pharmacologically unique,beta-blocker and ... chronic,heart failure. If approved by the FDA, ...
    Cached Biology Technology:Codexis Names Vice President, Intellectual Property 2Spectral to bring anti-sepsis therapy to the U.S. market 2Spectral to bring anti-sepsis therapy to the U.S. market 3FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma 2FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma 3
    (Date:11/21/2014)... 2014 According to a new ... (Video, RFID, Access Control, Intrusion Detection, Parking Management, Under ... Component Service Geography - Global Forecasts to 2020", published ... to be around $25 Billion in 2014 and is ... a CAGR of 8.69%. Browse 116 market ...
    (Date:11/21/2014)... 2014  Earlier this year Donald Spector , ... one of the most prolific inventors in the world, ... from Smartphones to third party agencies. Spector envisioned this ... of the earliest known patents in this area. Now ... military, child care, elder care and hospital applications. This ...
    (Date:11/21/2014)... 2014 Strict laws against distracted driving and ... North American and European automotive sector towards gesture recognition ... systems that are intuitive and able to retrieve information ... New analysis from Frost & Sullivan,s ... Europe and North ...
    Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
    ... [Brown University] Just as a company creates new, better ... its bottom line, an international team of researchers led by ... and performance before flooding the environment with new, improved versions ... plants with the same ancestor, called a clade, begin to ...
    ... growth and spread of breast cancer tumors may be ... strategies: blocking the enzyme needed to "energize" cancer cells ... with minimum exposure to healthy tissues, indicate researchers at ... in Chicago, Ill. "Once breast cancer metastases ...
    ... with information on the size of the carbon footprint ... make better, environmentally friendly choices. A Michigan State ... of the journal Nature Climate Change , said ... with nutritional information, could offer at least a short-term ...
    Cached Biology News:Like products, plants wait for optimal configuration before market success 2Interventional radiologists provide hope in delaying growth, spread of breast cancer 2Interventional radiologists provide hope in delaying growth, spread of breast cancer 3Nature paper calls for carbon labeling 2
    ... genetically engineered Klenow polymerase in which the 3 ... only the 5 to 3 polymerase activity. The ... the enzyme of choice for isotopic or biotin ... method, and for DNA sequencing by the Sanger ...
    ... a DNA-dependent RNA polymerase which is stringently ... efficiently synthesizes in vitro transcripts from almost ... a T7 promoter. Transcripts can be ... vitro translation, substrates in RNA processing systems, ...
    ... overproducer ATP: D-hexose 6- phosphotransferase/D-glucose-6-phosphate: ... unit of HK will phosphorylate ... 1 min at 25C at ... G6P-DH will oxidize 1 mol ...
    Goat polyclonal to Haptoglobin ( Abpromise for all tested applications). Antigen: Affinity purified human haptoglobin. Entrez GeneID: 3240 Swiss Protein ID: P00738...
    Biology Products: